Compare Cytokinetics Inc (CYTK) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Wells Fargo & Co — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Wells Fargo & Co trades at $87.68 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 24.6× Cytokinetics Inc's market cap, and Wells Fargo & Co pays a 2.29% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | WFC | |
|---|---|---|
Market Cap | $10.78B | $264.66B |
Sector | Technology | Financials |
52-Week High | $87.26 | $96.40 |
52-Week Low | $34.31 | $73.42 |
Enterprise Value | $10.88B | — |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Wells Fargo (WFC) trades at $87.25, down 0.4% today, with a bullish technical outlook from moving averages and a consensus price target of $97.64. The stock shows strong profitability with a net income margin of 25.97% and ROE of 13.13%, supported by steady revenue growth to $83.70 billion in 2025. Recent news highlights the launch of tokenized deposits for corporate clients, reflecting innovation in digital banking services.
The stock presents a value opportunity with a P/E of 12.68, but risks include volatile cash flows and recent earnings misses. Upside is driven by analyst optimism and dividend increases, while headwinds involve economic sensitivity and competitive pressures in banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
